DelveInsight added a report on the “Fibrodysplasia Ossificans Progressiva Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Fibrodysplasia Ossificans Progressiva. The launch of emerging therapies will significantly impact the Fibrodysplasia Ossificans Progressiva market.
Fibrodysplasia Ossificans Progressiva Overview
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.
Some of the key highlights of the Fibrodysplasia Ossificans Progressiva Market Report
- As per the analysis of Delveinsight, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in Japan was found to be 95, in 2017.
- FOP has a prevalence rate of 0.08 per 100,000 people.
- As per the Delveinsight’s analysis, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in the seven major markets was found to be 630 in 2017. In the United States total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) was found to be 293 in 2017.
- Fibrodysplasia Ossificans Progressiva companies included such as Ipsen, Regeneron Pharmaceuticals, Ipsen, BioCryst, Keros Therapeutics, and others
- Fibrodysplasia Ossificans Progressiva drugs included such as Palovarotene, Garetosmab (REGN2477), BLU-782, BCX9250, KER-047, and others
Get a sample copy of the report @ Fibrodysplasia Ossificans Progressiva Market Share
Fibrodysplasia Ossificans Progressiva Symptoms
The symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restriction of motion at various joints, severely limiting the activities of daily living and the quality of life of such patients by the third decade of life.
Fibrodysplasia Ossificans Progressiva Mutations
Mutations in the ACVR1 gene causes fibrodysplasia ossificans progressiva. The underlying genetic mutation in FOP alters the signals that regulate the induction of cell differentiation leading to bone formation.
Fibrodysplasia Ossificans Progressiva Cause
Extra-skeletal bone formation causes a progressive loss of mobility as the joints become affected. Inability to fully open the mouth may cause difficulty in speaking and eating. Over time, people with this disorder may experience malnutrition due to their eating problems. They may also have breathing difficulties as a result of extra bone formation around the rib cage that restricts expansion of the lungs.
Do you know about Fibrodysplasia Ossificans Progressiva Market Size?
Fibrodysplasia Ossificans Progressiva Epidemiology Segmentation
- Total prevalent cases
- Total diagnosed prevalent cases
- Gender-specific diagnosed prevalent cases
- Age-specific diagnosed prevalence cases
Fibrodysplasia Ossificans Progressiva Market Outlook
Fibrodysplasia Ossificans Progressiva (FOP) is one of the rarest and most disabling genetic conditions known to medicine. FOP causes the soft tissues to transform permanently into the bone; these bones aberrantly grow in the muscles, tendons, ligaments, and other connective tissues, forming bridges of extra bone across the joints.
Fibrodysplasia Ossificans Progressiva Market Insights
Presently, there is no definitive medical treatment for FOP, and the only management strategy is supportive in nature. The current management considerations are classified as Class I, Class II, and Class III medications along with few muscle relaxants and special medical considerations including injury prevention, scalp nodules, maintaining respiratory health and capacity, Infection precautions, particularly during the flu season. Also, the market holds substitutes for Acute & Chronic Pain Management in FOP.
Fibrodysplasia Ossificans Progressiva Emerging Drugs Analysis
Although Fibrodysplasia Ossificans Progressiva (FOP) pipeline was not very robust previously, currenty there are several potential players with their promising therapies in early stages of clinical development. Although Palovarotene is the only late-stage product upcoming for FOP, it is currently on a partial hold followed by another promising antibody Garetosmab in phase II clinical investigations and gene therapy in Phase I BLU-782. Other drugs such as BCX9250 and KER-047 are in the early stages of clinical development
Download Sample Report @ Fibrodysplasia Ossificans Progressiva Market Research Report
Table of content
1. Key Insights
2. Executive Summary of Fibrodysplasia Ossificans Progressiva (FOP)
3. Competitive Intelligence Analysis for Fibrodysplasia Ossificans Progressiva (FOP)
4. Fibrodysplasia Ossificans Progressiva (FOP): Market Overview at a Glance
5. Fibrodysplasia Ossificans Progressiva (FOP): Disease Background and Overview
6. Patient Journey
7. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Fibrodysplasia Ossificans Progressiva (FOP) Unmet Needs
10. Key Endpoints of Fibrodysplasia Ossificans Progressiva (FOP) Treatment
11. Fibrodysplasia Ossificans Progressiva (FOP) Marketed Products
12. Fibrodysplasia Ossificans Progressiva (FOP) Emerging Therapies
13. Fibrodysplasia Ossificans Progressiva (FOP): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Fibrodysplasia Ossificans Progressiva (FOP)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
